MGMT promoter methylation in plasma of glioma patients receiving temozolomide

Valentina Fiano; Morena Trevisan; Elisa Trevisan; Rebecca Senetta; Anna Castiglione; Carlotta Sacerdote; Anna Gillio‐Tos; Laura De Marco; Chiara Grasso; Michela Magistrello; Fabrizio Tondat; Roberta Rudà; Paola Cassoni; Riccardo Soffietti; Franco Merletti

doi:10.1007/s11060-014-1395-4

JOURNAL ARTICLE

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

Valentina Fiano Morena Trevisan Elisa Trevisan Rebecca Senetta Anna Castiglione Carlotta Sacerdote Anna Gillio‐Tos Laura De Marco Chiara Grasso Michela Magistrello Fabrizio Tondat Roberta Rudà Paola Cassoni Riccardo Soffietti Franco Merletti

Year: 2014 Journal: Journal of Neuro-Oncology Vol: 117 (2)Pages: 347-357 Publisher: Springer Science+Business Media

DOI: 10.1007/s11060-014-1395-4

Get Full-Text PDF Get Analytical Report

Keywords:

Temozolomide Methylation Glioma Methyltransferase O-6-methylguanine-DNA methyltransferase Oncology Hazard ratio Medicine Biomarker DNA methylation Concordance Promoter Cancer research Internal medicine Confidence interval Biology Gene Gene expression Genetics

Metrics

Cited By

3.16

FWCI (Field Weighted Citation Impact)

Refs

0.91

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Glioma Diagnosis and Treatment

Health Sciences → Medicine → Genetics

Epigenetics and DNA Methylation

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Histone Deacetylase Inhibitors Research

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

Metrics

Citation History

Topics

Related Documents

MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide.

Prognostic significance of MGMT promoter methylation in diffuse glioma patients

MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07).

Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients

MGMT promoter methylation and temozolomide response in choroid plexus carcinoma